Alvocidib (Flavopiridol)
Revision as of 22:15, 13 June 2018 by Warner-admin (talk | contribs) (Text replacement - "Category:Drug index" to "Category:Drugs")
Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
Diseases for which it is used
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)
Also known as
- Code names: HMR 1275, L-868275